Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

by Hentzien M, Owen A, Strub-Wourgaft N, Pérez-Casas C, Trøseid M, Calmy A. Frontiers in Microbiology 2022; 13:998287. doi: 10.3389/fmicb.2022.998287

Summary: This opinion piece highlights possible strategies to optimize and protect current and future therapeutic options to treat the most vulnerable patients. The authors highlight several crucial issues that warrant urgent attention for the use of emerging treatment options and call for combination therapies to be tested in adequately powered clinical trials in immunocompromised patients, both in wealthy and in low-income countries where HIV-driven immunosuppression is prevalent. If higher efficacy is confirmed, the diversity of possible combinations will enable the tailoring of therapeutic options to individual patient needs (e.g., avoiding drug-drug interactions in transplant patients) as well as their specific regional context (e.g., oral-only combinations).

The post Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants first appeared on DNDi.